Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer

Journal of Pathology

Volumn 186, Issue 3, 1998, Pages 240-246

  O'Connell, Joe ^a   Bennett, Michael W ^a   O'Sullivan, Gerald C ^a   Roche, Desmond ^a   Kelly, Jacquie ^a   Collins, J Kevin ^a   Shanahan, Fergus ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

Adenocarcinoma; Apoptosis; Colon cancer; Fas ligand; Immune privilege; In situ hybridization

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MESSENGER RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; COLON ADENOCARCINOMA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; COLONIC NEOPLASMS; EPITHELIAL CELLS; FAS LIGAND PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MEMBRANE GLYCOPROTEINS; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0031789409     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199811)186:3<240::AID-PATH173>3.0.CO;2-L     Document Type: Article

References (40)

1. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
2. Mountz JD, Zhou T, Bluethmann H, Wu J, Edwards CK. Apoptosis defects analyzed in TcR transgenic and Fas transgenic lpr mice. Int Rev Immunol 1994; 11: 321-342.
3. Alderson MR, Tough TW, Davis-Smith T, et al. Fas Iigand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181:71-77.
4. Daniel PT, Krammer PH. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 1994; 152: 5624-5632.
5. Berke G. The CTL's kiss of death. Cell 1995; 81: 9-12.
6. Eischen CM, Schilling JD, Lynch DH, Krammer PH, Leibson PJ. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996; 156: 2693-2699.
7. Liu C-C, Walsh CM, Eto N, Clark WR, Young JD-E. Morphologic and functional characterization of perforin-deficient lymphokine-activated killer cells. J Immunol 1995; 155: 602-608.
8. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 1997; 3: 294-300.
9. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806-3813.
10. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 1995; 166: 236-246.
11. Hahne M, Renno T, Schröeter M, et al. Activated B cells express functional Fas ligand. Eur J Immunol 1996; 26: 721-724.
12. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184: 429-440.
13. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192.
14. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
15. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396-402.
16. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46: 317-322.
17. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 270: 109-112.
18. Arai H, Chan SY, Bishop DK, Nabel GJ. Inhibition of the alloantibody response by CD95 ligand. Nature Med 1997; 3: 843-848.
19. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nature Med 1996; 2: 317-322.
20. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
21. Hahne M, Rimoldi D, Schröter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
22. Strand S. Hofmann WJ. Hug H. et al. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
23. Niehans GA. Brunner T. Frizelle SP. et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-1012.
24. Saas P. Walker PR. Hahne M. et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-1178.
25. Shiraki K. Tsuji N. Shioda T. Isselbacher KJ. Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997; 94: 6420-6425.
26. Möller P, Walczak H. Riedl S. Sträter J. Krammer PH. Paneth cells express high levels of CD95 iigand transcripts. A unique property among gastrointestinal epithelia. Am J Pathol 1996; 149: 9-13.
27. Sträter J, Wellisch I, Riedl S, et al. CD95 (Apo-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 1997; 113: 160-167.
28. Fulda S. Sieverts H, Friesen C. Herr I, Debatin KM. The CD95 (Apo-1/ Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-3829.
29. Herr I, Wilhelm D, Böhler T, Angel P. Debatin KM. Activation of CD95 (Apo-1/Fas) signalling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 1997; 16: 6200-6208.
30. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996; 5: 7-16.
31. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129-1135.
32. Behrens TW. Mueller DL. Bel-x and the regulation of survival in the immune system. Immunol Res 1997; 16: 149-160.
33. Peter ME, Kischkel FC, Scheuerpflug CG, Medema JP, Debatin KM, Krammer PH. Resistance of cultured peripheral T cells towards activationinduced cell death involves a lack of recruitment of FLICE (MACH/ Caspase 8) to the CD95 death-inducing signalling complex. Eur J Immunol 1997: 27: 1207-1212.
34. Akbar AN, Salmon M. Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Immunol Today 1997; 18: 72-76.
35. Möller P, Korefz K, Leithäuser F, et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily. in normal and neoplastic colon epithelium. Int J Cancer 1994: 57: 371-377.
36. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allograft. Proc Natl Acad Sci USA 1997: 94: 3943-3947.
37. Kang S-M, Schneider DB, Lin Z. et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Mad 1997; 3: 738-743.
38. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nature Med 1997; 3: 165-170.
39. Lau HT, Stoeckert CJ. FasL - too much of a good thing? Nature Med 1997; 3: 727-728.
40. Rayner AA, Grimm EA, Lotze MT. Lymphokine-activated killer (LAK) cells: analysis of factors relevant to the immunotherapy of human cancer. Cancer 1985; 55: 1327-1333.